DE69725577D1 - Verwendung von mitteln die den wachstumsfaktor beeinflussen - Google Patents

Verwendung von mitteln die den wachstumsfaktor beeinflussen

Info

Publication number
DE69725577D1
DE69725577D1 DE69725577T DE69725577T DE69725577D1 DE 69725577 D1 DE69725577 D1 DE 69725577D1 DE 69725577 T DE69725577 T DE 69725577T DE 69725577 T DE69725577 T DE 69725577T DE 69725577 D1 DE69725577 D1 DE 69725577D1
Authority
DE
Germany
Prior art keywords
growth factor
affect
agents
preparing
high density
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69725577T
Other languages
English (en)
Other versions
DE69725577T2 (de
Inventor
Matti Siren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIONERIS LIDINGOE AB
Original Assignee
BIONERIS LIDINGOE AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIONERIS LIDINGOE AB filed Critical BIONERIS LIDINGOE AB
Application granted granted Critical
Publication of DE69725577D1 publication Critical patent/DE69725577D1/de
Publication of DE69725577T2 publication Critical patent/DE69725577T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69725577T 1996-06-24 1997-06-23 Verwendung von mitteln die den wachstumsfaktor beeinflussen Expired - Fee Related DE69725577T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9602463A SE9602463D0 (sv) 1996-06-24 1996-06-24 The use of growth factor modulating compounds
SE9602463 1996-06-24
PCT/SE1997/001115 WO1997049408A1 (en) 1996-06-24 1997-06-23 The use of growth factor modulating compounds

Publications (2)

Publication Number Publication Date
DE69725577D1 true DE69725577D1 (de) 2003-11-20
DE69725577T2 DE69725577T2 (de) 2004-08-05

Family

ID=20403108

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69725577T Expired - Fee Related DE69725577T2 (de) 1996-06-24 1997-06-23 Verwendung von mitteln die den wachstumsfaktor beeinflussen

Country Status (7)

Country Link
EP (2) EP0910383B1 (de)
AT (1) ATE251909T1 (de)
AU (1) AU3469597A (de)
CA (1) CA2261706C (de)
DE (1) DE69725577T2 (de)
SE (1) SE9602463D0 (de)
WO (1) WO1997049408A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143596A0 (en) * 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
FI20021570A0 (fi) * 2002-09-03 2002-09-03 Gallen Kallela Siren Janne Päällystetyn kirurgisen stentin paranneltu rakenne
EP2621273A4 (de) * 2010-09-30 2014-03-05 Normoxys Inc Polyphosphat- und pyrophosphatderivat von sacchariden

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
SE8605063D0 (sv) * 1986-11-26 1986-11-26 Matti Siren Derivatives of cyclohexane
SE464059C (sv) * 1988-09-15 1997-06-02 Perstorp Ab Användning av inositoltrifosfat för framställning av läkemedel
CA2019878A1 (en) * 1989-09-13 1991-03-13 Robert Sabin Method of treatment of rheumatoid arthritis using phytic acid
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
SE470511B (sv) * 1992-11-05 1994-06-27 Perstorp Ab Användning av inositolreisfosfat för beredning av läkemedel
SE502989C2 (sv) * 1993-11-22 1996-03-04 Perstorp Ab Användning av en inositoltrisfosfatester för beredning av läkemedel
SE502990C2 (sv) * 1993-11-22 1996-03-04 Perstorp Ab Användning av en inositoltrisfosfatester för beredning av ett smärtstillande läkemedel

Also Published As

Publication number Publication date
EP0910383B1 (de) 2003-10-15
ATE251909T1 (de) 2003-11-15
SE9602463D0 (sv) 1996-06-24
DE69725577T2 (de) 2004-08-05
WO1997049408A1 (en) 1997-12-31
CA2261706C (en) 2009-06-09
EP0910383A1 (de) 1999-04-28
EP1216705A2 (de) 2002-06-26
EP1216705A3 (de) 2003-11-12
AU3469597A (en) 1998-01-14
CA2261706A1 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
ATE179892T1 (de) Verwendung von lipid-gebundener glykoaminoglykanen zur behandlung der rheumatoider arthritis
MX9302932A (es) Nuevas 4-aza-5&-androstan-3-onas 7b-substituidas como inhibidores de la5&-reductasa.
NO944997L (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
ATE169616T1 (de) Zwischenverbindungen zur herstellung von fungiziden
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69202739D1 (de) Gemischtes Alkylmethylsiloxane zur Hautpflege.
DE69534002D1 (de) Verwendung von Phosphatidylserinen zur Herstellung eines Arzneimittels zur Verbesserung der Gehirntätigkeit
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
ATE49882T1 (de) Sebosuppressive kosmetische mittel, enthaltend benzylalkohol-derivate.
MX9704050A (es) P-amidinobencilamidas de dipeptido novedosas con radicales sulfonilo o aminosulfonilo en terminal n.
DE59108850D1 (de) Wirkstofffreie Liposomen zur Behandlung von Atherosklerose
ATE251909T1 (de) Verwendung von mitteln die den wachstumsfaktor beeinflussen
ES2077891T3 (es) Empleo de oximeter derivados para la biorregulacion de las plantas.
ATE247474T1 (de) Verwendung von inosittriphosphat zur herstellung von arzneimitteln
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
ATE49881T1 (de) Sebosuppressive kosmetische mittel, enthaltend alkoxyaryl-alkanole.
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
AT400095B (de) Zahnärztliches handstück für die behandlung von zähnen mit laserstrahlen
ATE139696T1 (de) Verwendung von benzothiazepinen zur herstellung von arzneimitteln zur behandlung von epileptischen anfällen
DE69131058D1 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
FI965171A (fi) Oksatsofosforiinien, esimerkiksi ifosfamidin, enantiomeerien käyttö kasvainten hoidossa sivuvaikutuksien vähentämiseksi
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE3684474D1 (de) Verwendung von cobalt proto-und mesoporphyrin zur herstellungeines arzneimittels zur hemmung des endocrinen systems.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee